PER® Chemotherapy Foundation Symposium (CFS) | Conference

Navigating the Increasing Complexity of Therapeutic Sequencing for Relapsed/Refractory Multiple Myeloma

November 8th 2020

The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.

Need for Germline Testing Becomes Increasingly Pronounced in Oncology

November 6th 2020

Mark E. Robson, MD, discusses how a strong cognizance of germline testing is becoming increasingly important in the field of oncology, across an array of tumor types.

Dr. Markman on the Benefit of PARP Inhibitors in Ovarian Cancer

November 6th 2020

Maurie Markman, MD, discusses the utility of PARP inhibitors in ovarian cancer.

Dr. Yu on the Role of Radiation in Prostate Cancer

November 6th 2020

James B. Yu, MD, MHS, discusses the utility of radiation in men with prostate cancer.

NCI Director Talks Response to COVID-19 Crisis, Focuses on Overcoming Disruptions in Cancer Care

November 6th 2020

Norman E. “Ned” Sharpless, MD, discusses the efforts that The National Cancer Institute has made to combat the coronavirus disease 2019 pandemic.

Hudis Emphasizes Need for Cancer Research Funding During CFS® Keynote

November 6th 2020

Clifford A. Hudis, MD, CEO highlights cancer mortality and how it has steadily declined in the United States since 1975.

Unlocking the Potential of Targeted Treatment Options for HCC

November 6th 2020

Targeted agents have restructured the treatment paradigm for patients with advanced hepatocellular carcinoma. The present challenge is to identify the patients most likely to benefit from frontline treatment regimens.

Dr. Weber on the Evolution of Melanoma Treatment

November 5th 2020

Jeffrey S. Weber, MD, PhD, discusses the evolution of the treatment paradigm in melanoma.

Immunotherapy in Gynecologic Cancers Shows Progress but Has a Long Way to Go

November 5th 2020

Ursula Matulonis, MD, highlights immunotherapy agents have demonstrated moderate clinical activity for patients with gynecologic cancers, however they fail to yield significant response rates in both the newly-diagnosed and recurrent settings.

Dr. Jhaveri on Outlining First-Line Treatment in HER2+ Breast Cancer

November 5th 2020

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

x